Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Jin Li et al.   LANCET ONCOLOGY

The preclinical development of regorafenib for the treatment of colorectal cancer

(2014) Koh Miura et al.   Expert Opinion on Drug Discovery

EphB4 Cellular Kinase Activity Assayed Using an Enzymatic Protein Interaction System

(2013) Tom Wehrman et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

(2013) Roberta Schmieder et al.   INTERNATIONAL JOURNAL OF CANCER

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

(2012) D Strumberg et al.   BRITISH JOURNAL OF CANCER

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

(2012) K. Mross et al.   CLINICAL CANCER RESEARCH

Regorafenib for cancer

(2012) Dirk Strumberg et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial

(2012) Suzanne George et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia

(2012) R Swords et al.   LEUKEMIA

Protein Binding: Do We Ever Learn?

(2011) Markus A. Zeitlinger et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

(2011) Peter S. Hammerman et al.   Cancer Discovery

GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling

(2010) A. Bai et al.   CANCER RESEARCH

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

(2010) Dennis A. Smith et al.   NATURE REVIEWS DRUG DISCOVERY

Growth factors in tumor microenvironment

(2009) Xuejing Zhang   Frontiers in Bioscience-Landmark

Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics

(2009) Stephan Schmidt et al.   JOURNAL OF PHARMACEUTICAL SCIENCES